Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status Proceeding/Conference:Journal of Clinical Oncology | 2016 | 176 | ||
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study Proceeding/Conference:European Society for Medical Oncology (ESMO) Asia Congress, 2017 | 2017 | 46 |